Baidu
map

JAHA:他汀类药物与糖尿病发生呈时间剂量相关性

2019-04-17 不详 MedSci原创

他汀类药物被越来越广泛地用于一级预防,但是他汀药物与糖尿病发生的相关性问题不容忽视。本研究纳入了2005-2012年年龄≥40岁的复合他汀类药物适应症的高血脂患者,主要终点事件是接受药物治疗后的新发糖尿病。在2162119名复合他汀药物治疗适应症的高血脂患者中,有29.5%患者曾经使用过他汀类药物,经过平均3.9年时间的随访,相比于从没使用过他汀药物患者,使用过他汀药物患者的糖尿病风险明显更高(H

他汀类药物被越来越广泛地用于一级预防,但是他汀药物与糖尿病发生的相关性问题不容忽视。

本研究纳入了2005-2012年年龄≥40岁的复合他汀类药物适应症的高血脂患者,主要终点事件是接受药物治疗后的新发糖尿病。在2162119名复合他汀药物治疗适应症的高血脂患者中,有29.5%患者曾经使用过他汀类药物,经过平均3.9年时间的随访,相比于从没使用过他汀药物患者,使用过他汀药物患者的糖尿病风险明显更高(HR:1.88; 95% CI, 1.85–1.93),且他汀药物使用的时间越长,糖尿病发生风险越高。另外,他汀药物使用的剂量和强度同样与糖尿病的发生风险相关。

研究结果显示,在服用他汀类药物作为一级预防的患者中,药物剂量和服用时间与糖尿病的发生风险均呈相关性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837669, encodeId=e78b183e669bd, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Sep 08 05:22:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044550, encodeId=636720445500c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Oct 31 10:22:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268120, encodeId=5f3d1268120aa, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Apr 19 01:22:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042390, encodeId=0b2010423909a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 13:22:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837669, encodeId=e78b183e669bd, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Sep 08 05:22:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044550, encodeId=636720445500c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Oct 31 10:22:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268120, encodeId=5f3d1268120aa, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Apr 19 01:22:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042390, encodeId=0b2010423909a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 13:22:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837669, encodeId=e78b183e669bd, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Sep 08 05:22:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044550, encodeId=636720445500c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Oct 31 10:22:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268120, encodeId=5f3d1268120aa, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Apr 19 01:22:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042390, encodeId=0b2010423909a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 13:22:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-19 仁心济世
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837669, encodeId=e78b183e669bd, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Sep 08 05:22:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044550, encodeId=636720445500c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Oct 31 10:22:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268120, encodeId=5f3d1268120aa, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Apr 19 01:22:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042390, encodeId=0b2010423909a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 17 13:22:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-17 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

盘点:JACC四月第二期研究一览

1.非致密性心肌病家系的心脏表型和基因特征研究DOI: 10

四大神刊:双杀!柳叶刀揭示中国人吃饭、喝酒都“要命”!

梅斯医研社,中国医学精英的内容头等舱。

Circulation:2型糖尿病的诊断年龄与心血管和死亡风险的关联

由此可见,诊断T2DM的年龄对于生存和心血管风险具有重要的预后价值,对于确定临床决策和指导性治疗的危险因素干预的时间和强度具有重要意义。这些观察结局扩大了对年轻个体预防/延迟T2DM发作的支持力度。

JACC:伴糖尿病冠心病患者PCI和CABG治疗预后无明显差异

EXCEL临床随机对照试验结果显示对于左主干冠脉(LMCAD)病变患者,冠脉搭桥(CABG)和经皮冠脉介入治疗(PCI)的三年主要终点事件发生率相似,然而这对于高风险患者如伴有糖尿病的患者是否有同样的结果尚不清楚。本研究纳入分析了1905例LMCAD病变患者,其中554名伴有糖尿病,随机1:1分至PCI支架植入组和CABG组,并根据是否有糖尿病进行分层,主要终点事件是3年全因死亡、卒中和心梗的复合

JACC:标准化治疗可改善心源性休克预后

心源性休克(CS)是一种多因素的血流动力学复杂的综合征,死亡率高。尽管在再灌注和机械循环支持方面取得了进展,但CS的治疗方法仍然存在很大的差异,且效果不佳。本研究的目的旨在评估以团队为基础的标准化方法是否可以改善CS的预后。本研究纳入分析了204名CS患者,并对患者的CS病因、人口统计学特征、右心导管插入术、机械循环支持使用和生存率进行了统计,在基线水平和CS诊断后24小时测量了患者的心输出功率(

JACC:经导管主动脉瓣置换术后感染性心内膜炎的远期发生率研究

接受外科主动脉瓣置换术(SAVR)后的患者发生感染性心内膜炎(IE)的风险会更高,然而经导管主动脉瓣置换术(TAVR)后的IE发生风险尚不清楚。本研究纳入分析了丹麦国家数据库中的2632名接受TAVR治疗和3777名接受SAVR治疗的无IE病史的患者,经过平均3.6年时间的随访,4.4%的TAVR组患者和4.9%的SAVR组患者出现感染性心内膜炎,两组患者从手术到IE住院之间的平均时间间隔分别为3

Baidu
map
Baidu
map
Baidu
map